ReCode Therapeutics’ Post

In our poster unveiled at #AACR2024 genOway and Innate Pharma demonstrated an increased ADCC in the hFcγR model following treatment with Obitunuzumab, an antibody engineered to display enhanced Fc binding, relative to Rituximab, a monoclonal antibody with a regular hIgG1 Fc 👉 https://lnkd.in/e5-wvABR     The new humanized FcγR mouse model enables a translatable assessment the Fc-mediated function of therapeutic antibodies 👉 https://lnkd.in/ezKwdc5E   Efficacy data was generated in collaboration with over 10 biopharma partners, including argenx, Seismic Therapeutic and Innate Pharma, in the field of autoimmunity and immuno-oncology 👉 https://lnkd.in/epXUmS3z #preclinicalservices #preclinicalresearch #preclinicalmodels

Lipid Nanoparticle (LNP)- Mediated Delivery of BioPROTACs: BioPROTACs, also known as ubiquibodies, are recombinant protein-based degraders created by fusing a protein-based binder to an E3 ligase or E3 adapter. These biologics selectively ubiquitinate target proteins for ubiquitin-proteasome system (UPS)-mediated degradation, differing from small-molecule PROTACs by directly fusing warheads to E3 domains without relying on endogenous ligase recruitment. A recent study reported by researchers from the University of Pennsylvania utilized lipid nanoparticles (LNPs) for bioPROTAC encapsulation, achieving 95% GFP-KRAS elimination and doubling delivery efficiency over Lipofectamine. BioPROTACs effectively degraded endogenous Ras across multiple cell types. Their modular format allows for easy reprogramming to target various clinically relevant proteins. The study demonstrated rapid, specific intracellular protein degradation and significant antiproliferative effects of Ras-degrading bioPROTACs in pancreatic cancer cells, highlighting their potential as a therapeutic modality for undruggable or resistant proteins. Link to the article: https://lnkd.in/gnSY8B5c #bioprotac #ubiquibodies #AdPROM #protac #cancertherapy #lipidnanoparticles #lnp #nanoparticles #targetedproteindegradation Rebecca Haley David Gonzalez-Martinez Lukasz Bugaj George Burslem Michael J Mitchell & Andrew Tsourkas

🔍 The Pulmonary Arterial Hypertension (PAH) therapeutic landscape is evolving with a variety of approaches targeting different pathways. Established treatments like ambrisentan, bosentan, riociguat, treprostinil, and epoprostenol continue to provide vital options for managing the disease. Exciting new developments are underway, including fusion proteins such as sotatercept, monoclonal antibodies, and gene-modified cell therapies like Northern Therapeutics' Aurora-GT, currently in Phase III trials. Research into oral, intravenous, and inhalational therapies is also expanding potential treatment avenues. Though challenges persist, these ongoing innovations highlight the commitment to enhancing treatment strategies and broadening options for PAH patients. #PulmonaryArterialHypertension #Pharmaceuticals #Innovation #Healthcare #Biotech 🔗 https://lnkd.in/g5qPutXz

There are two major trends in drug development for nAMD: extending dosing intervals and reducing the occurrence of macular atrophy. In the results of two Phase 2 studies, which enrolled over 360 subjects, IBI302 improved BCVA and macular edema in patients with nAMD significantly, extended dosing intervals, and had the potential to prevent the development of macular atrophy. Next, we will further investigate the long-interval dosing efficacy and safety of high-dose IBI302 in the Phase 3 STAR trial, hoping to bring a new generation of anti-VEGF agents to patients with nAMD.

In our poster unveiled at #AACR2024, we demonstrated that an anti-CD20 antibody depleted B cells in the humanized FcγR mouse model, while its silenced Fc variant did not 👉 https://lnkd.in/eJw4irri The new humanized FcγR mouse model enables a translatable assessment the Fc-mediated function of therapeutic antibodies 👉 https://lnkd.in/ezKwdc5E Efficacy data was generated in collaboration with over 10 biopharma partners, including argenx, Seismic Therapeutic and Innate Pharma, in the field of autoimmunity and immuno-oncology 👉 https://lnkd.in/epXUmS3z #preclinicalservices #preclinicalresearch #preclinicalmodels

Learn more about unleashing the promise of peptide therapeutics, prized for their potency, low toxicity, and specificity in this webinar with Thermo Fisher Scientific: https://ow.ly/Byj050TJCfB Discover the innovative strides being made in developing oral delivery solutions for these revolutionary therapies in treating conditions like metabolic disorders, cancers, and autoimmune diseases, opening the doors to more widespread applications. Join an expert from Thermo Fisher Scientific for deep insights into moving forward with peptide therapeutics. You will gain a deeper understanding of the barriers to oral delivery, technological innovations transforming the oral peptide landscape, regulatory framework considerations, and the outlook for these important therapeutics.

Choosing the right partners for your IVT mRNA synthesis workflow is critical in the path to developing mRNA therapeutics. Start your DNA plasmid template on the right foot with our ISO 13485 certified competent cells that are tailored to your research needs. https://hubs.li/Q02R6lTx0 #mRNAsynthesis #mRNAtherapeutics #mRNAvaccines #mRNAresearch

CSL Vifor and Travere Therapeutics announce European Commission approves FILSPARI(sparsentan) for the treatment of IgA Nephropathy (IgAN). First non-immunosuppressive therapy for the treatment of IgAN approved in Europe. Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist with high selectivity for the endothelin A receptor (ETAR) and the angiotensin II subtype 1 receptor (AT1R). Pre-clinical data have shown that blockade of both endothelin type A and angiotensin II type 1 pathways in forms of rare chronic kidney disease, protects podocytes, prevents glomerulosclerosis and mesangial cell proliferation, and reduces proteinuria. Chemenu has been working to develop more compounds for drug discovery. Here comes the building blocks we can provide: https://lnkd.in/dCcFVM9H #FILSPARI #sparsentan #IgAN #RE-021 #ETA #AT1 #buildingblocks

Myc Proto Oncogene Protein Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, and Companies by DelveInsight | Biogenera SpA, Ceptur Therapeutics Inc, Cothera Bioscience, more: Myc Proto Oncogene Protein Clinical Trials As per DelveInsight’s assessment, globally, Myc Proto Oncogene Protein pipeline constitutes 12+ key companies continuously working towards developing 12+ Myc Proto Oncogene Protein treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Challenges and Advances of the Stability of #mRNA Delivery Therapeutics Despite #mRNAtherapy having US FDA approval and efficacy, lipid #nanoparticles face poor stability at room temperature, limiting their applications in various geographic regions with disparities in infrastructure and technology. This #review aims to dissect the issue of stability inherent in #lipidnanoparticles and other #mRNAdelivery platforms such as polymer-based materials and protein derivative materials. A comprehensive analysis of the current landscape of mRNA delivery systems, highlighting their successes and limitations, and paving the way for future advancements in this rapidly evolving field. Read below: https://buff.ly/3WngYvF